Inside the research
IDEXX Laboratories, Inc.
IDXX Research profile · latest available data
Price overview
$519.26
▲ +5.87 (+1.1%)
| 52w hi | $766.68 |
|---|---|
| 52w lo | $504.70 |
| Vol | 331.10K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.40
| Short | -0.66 |
|---|---|
| Medium | -0.33 |
| Long | -0.02 |
computed 2026-09-27
Key fundamentals
IDEXX Laboratories, Inc.
Healthcare · Diagnostics & Research
| Market cap | $40.91B |
|---|---|
| Enterprise value | $41.81B |
| Trailing P/E | 36.49x |
| Forward P/E | 31.02x |
| EV / EBITDA | 25.78x |
| P / S (ttm) | 9.00x |
| Profit margin | 25.0% |
| Return on equity | 74.2% |
| Revenue growth | +9.7% |
| Earnings growth | +17.6% |
| Debt / equity | 67.97 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.21 | |
| Sector | +0.08 | |
| Technical | -0.47 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Risk Metrics
| Beta vs SPX | 0.96 |
|---|---|
| Corr SPX | 0.41 |
| Annual vol | 37.6% |
| Annual ret | +7.9% |
| Sharpe | 0.21 |
| Max DD | -34.2% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $709.14 |
|---|---|
| High / Low | $805.00 / $470.00 |
| Median | $712.50 |
| Analysts | 14 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 5 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-04-28 | UBS | → Neutral |
| 2026-04-15 | Citigroup | → Neutral |
| 2026-03-31 | Stifel | → Buy |
| 2026-02-09 | Piper Sandler | → Neutral |
| 2026-02-05 | Barclays | → Overweight |
| 2026-02-03 | UBS | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-05-15 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-03-26 | Officer / Director Change, Exhibits | read |
| 2026-02-13 | Officer / Director Change | read |
| 2026-02-02 | Earnings Release, Exhibits | read |
| 2026-01-13 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-11-13 | Material Agreement, Material Obligation… | read |
| 2025-11-03 | Earnings Release, Exhibits | read |
| 2025-10-07 | Officer / Director Change, Exhibits | read |
| 2025-08-04 | Earnings Release, Exhibits | read |
| 2025-07-10 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-30 | HOOLEY JOSEPH L | Grant | 49 | $27.38K | |
| 2026-06-01 | FENNELL GEORGE | Executive Vice President | Option exercise | 639 | — |
| 2026-06-01 | FENNELL GEORGE | Executive Vice President | Withheld for tax | 284 | $160.97K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $4.30B | +10.0% | |
| Gross profit | $2.38B | +10.5% | |
| Operating income | $1.36B | +14.8% | |
| Net income | $1.06B | +15.9% | |
| Cash from ops | $1.18B | +17.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $510.94 | $520.16 | $507.01 | $519.26 | 331.10K |
| Sep 24 | $520.88 | $524.12 | $511.73 | $513.39 | 328.30K |
| Sep 23 | $517.20 | $523.22 | $516.88 | $522.02 | 364.20K |
| Sep 22 | $519.27 | $523.95 | $511.73 | $521.50 | 476.50K |
| Sep 21 | $511.65 | $518.96 | $506.22 | $515.30 | 513.20K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →